Vasopharm completes patient enrollment for phase 3 traumatic brain injury trial (NOSTRA)
vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, is pleased to announce that enrolment into the…
Read More...
Read More...
